38 results
424B5
ACIU
AC Immune SA
15 Dec 23
Prospectus supplement for primary offering
5:27pm
on certain home country governance practices rather than the corporate governance requirements of Nasdaq.
We are a foreign private issuer … . As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country (in this case, Swiss) governance requirements and certain
6-K
EX-99.1
ACIU
AC Immune SA
26 Jun 23
Current report (foreign)
8:40am
of the Compensation, Nomination and Corporate Governance Committee ■ The Board of Directors proposes that: ■ Monika Bütler (election) ■ Roy Twyman (re - election … ) ■ Douglas Williams (re - election) be elected or re - elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term
6-K
ACIU
AC Immune SA
26 Jun 23
Current report (foreign)
8:40am
://ir.acimmune.com/governance) after the filing of the document with the Swiss Register of Commerce. The final results of the remaining agenda items … (https://ir.acimmune.com/governance) within 15 days:
Agenda Item 1: 2022 IFRS Consolidated Financial Statements, 2022 Statutory Financial Statements
6-K
EX-99.3
zf5iyf2
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
6-K
EX-99.1
dn3m0978rama1nu
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
6-K
e4lq zljnfr
24 Jun 22
Current report (foreign)
5:29pm
6-K
EX-99.2
p0dh9t hywt
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
6-K
EX-99.1
ho28wr4 iu
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
6-K
EX-99.4
0m8w1utfrysqishe682
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
c557vms76hmj1hn
25 Jun 21
Current report (foreign)
4:31pm
6-K
EX-99.1
dqvi ksccw
21 May 21
Notice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1
8:55am
6-K
EX-99.4
xucu9f7kwhzugo9
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
rwthwg79o0 r5lrv2ks
26 Jun 20
Current report (foreign)
4:51pm
6-K
EX-99.1
nsesej
22 May 20
Invitation to the Ordinary Shareholders' Meeting
8:40am
6-K
EX-99.3
87i79pewxbw8oj 809s9
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am